Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
[2]
Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoiso-merase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat, 2008, 107(69): 214.？
[3]
Ellis P, Barrett-Lee P, Johnson L, et al. Sequential doce-taxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase Ⅲ, randomized controlled trial[J]. Lancet, 2009,
[4]
373(9676): 1681-1692
[5]
K？nigsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients [J]. Cancer Invest, 2011, 29(2): 180-186.
[6]
Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple-negative breast cancer patients compared to non-triple negative patients[J]. Breast, 2010, 19(3): 246-248.
O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial[J]. J Clin Oncol Meeting Abstracts, 2009, 27(18S): 3.
[9]
Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer[J]. Anti-Cancer Drugs, 2007, 18(7): 835-837.
[10]
Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009)[J]. J Clin Oncol, 2008, 26(suppl 15): 43.
[11]
O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin？with or without cetuximab in patients with metastatic breast cancer (abstract 308)[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S32.
[12]
Tischkowitz M, Brunet JS, Bgin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 134.
[13]
Kennedy CR, Feng Gao, Julie A. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer[J]. J Surg Res, 2010, 163(1): 52-57.
[14]
Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3): 375？379.
[15]
Conforti R, Bidard FC, Michiels S, et al. Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S135.
[16]
Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol, 2008, 19(7): 1261-1265.
[17]
Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
[20]
Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 203.
[21]
Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience[J]. Ann Oncol, 2011, 22(4): 848-856.
[22]
Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efcacy[J]. J Clin Oncol, 2009, 27(15S): 551.
[23]
Anthony E, Dragun, MD, Jianmin Pan, et al. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol, 2011, 34(3): 231-237.
[24]
Freedman GM, Anderson PR, Li Tianyu, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J]. Cancer, 2009, 115(5): 946-951.
[25]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic signicance [J]. J Clin Oncol, 2007, 25(18S): 21088.
Kowalski PJ, Rubin MA, Kleei CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases[J]. Breast Cancer Res, 2003, 5(6): 217-222.
Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and in creased risk for recurrence in patients with triple-negative breast cancer[J]. Ann Oncol, 2008, 19(4): 669-674.
